Autolus Therapeutics plc
AUTL$614M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaLONDON647 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
AUTL News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
AUTO1
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
AUTO3 (CD19/22 CAR T cells
B Acute Lymphoblastic Leukemia
AUTO4
T Cell Non-Hodgkin Lymphoma
Obecabtagene autoleucel
Lupus Nephritis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AUTO1 | Phase 2 | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | - | - |
AUTO3 (CD19/22 CAR T cells | Phase 2 | B Acute Lymphoblastic Leukemia | - | - |
AUTO4 | Phase 2 | T Cell Non-Hodgkin Lymphoma | - | - |
Obecabtagene autoleucel | Phase 2 | Lupus Nephritis | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply